TL;DR
- Patient assistance programs create false hope by helping individual patients afford drugs while allowing manufacturers to keep prices high, which hurts the overall healthcare system and drives up costs for everyone
- Administrative chaos blocks access as 60% of patients don't know programs exist, each drug company sets different rules, and providers waste time on paperwork instead of treating patients
- Insurance companies fight back with dirty tactics like copay accumulators and maximizers that accept manufacturer coupons but don't count them toward deductibles, leaving patients with massive surprise bills
- Real reform requires structural change - ban insurance counter-tactics, standardize program rules across all companies, and focus on lowering actual drug prices instead of relying on charity band-aids
Table of Contents
Prescription drug costs are skyrocketing and patient assistance programs (PAPs) have emerged as a supposed lifeline for millions of Americans struggling to afford vital medications.
PAPs, especially if sponsored by pharmaceutical manufacturers, seem like compassionate solutions to the financial toxicity of modern healthcare. But there are fundamental problems with patient assistance programs beyond administrative challenges.
The False Promise of Pharmaceutical Safety Nets
Patient assistance programs are positioned as crucial safety nets for vulnerable populations facing high out of pocket costs. These programs are offered by manufacturers and independent foundations to connect patients with financial assistance for expensive drug therapies, otherwise unattainable. But these programs that help individuals can potentially harm the broader healthcare system. A policy paradox results that demands closer examination.
“While PAPs offer immediate relief to individual patients, they simultaneously operate as a market distortion tool that enables the maintenance of high list prices for expensive drug products, undermining established cost-control mechanisms within insurance plans,” notes research from Harvard Medical School and the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital.
Structural Problems Undermining Patient Support
Administrative Barriers and Fragmentation
PAPs have a stated mission of seamless patient access. Yet the system is plagued by administrative friction, opacity, and lack of standardization that collectively form significant barriers to the very populations most in need of assistance.
Despite the acute need for help with high out of pocket costs, eligible patients and providers frequently fail to utilize available programs. A primary barrier is a fundamental lack of awareness; nearly 60%of patients have limited or no knowledge of available medication support programs. This information gap disproportionately affects vulnerable populations, including the elderly, those with limited English proficiency, and individuals in underserved communities.
The eligibility criteria and application processes also lack uniformity and transparency. Each manufacturer sponsored PAP sets its own criteria regarding income, insurance status, and medical condition. But the information is often not publicly available. The application processes themselves vary dramatically across programs. And there is a maze of paperwork, verification requirements, and submission mechanisms that patients and providers must navigate separately for each medication.
The result is a fragmented landscape of patient financial support. PAPs are often tightly targeted at specific therapies and may or may not coordinate with the patient’s existing insurance plans. So the support provided is piecemeal and unreliable. This non-standardization limits the ability of the PAP system to serve as a reliable, universal safety net.
Administrative Burden on Healthcare Providers
The complexity of navigating PAPs and securing financial assistance imposes a massive administrative burden on healthcare providers and systems. And diverts essential resources away from direct patient care. This administrative friction is acutely felt in large health systems.
Providers report that time is diverted managing increasingly complex health plan requirements, such as prior authorization (PA), which must be secured before a patient can receive prescribed medications, tests, or procedures. Similar bureaucratic demands arise when attempting to secure PAP enrollment. The effort involves copious paperwork, phone calls, and dealing with varying submission mechanisms, forcing clinical staff to perform duplicative tasks outside of the primary clinical workflow.
The American Medical Association found that 86% of surveyed physicians reported that administrative requirements, such as prior authorizations, resulted in increased use of healthcare resources and waste, rather than the cost savings claimed by insurers.
This situation demonstrates a significant administrative inefficiency.The current lack of standardization serves a detrimental purpose for manufacturers. It allows them to tightly control the distribution and target population for their sponsored patient assistance programs. The system indirectly promotes a specific, high-cost prescription drug product.
The Financial War: Manufacturers vs. Insurance Plans
Manufacturer Strategies and Market Distortion
The creation of PAPs allows drug manufacturers to manage market share for their expensive drug products. Manufacturers exercise direct control over their proprietary PAPs, dictating which specific prescription drug receives assistance. This influence is crucial; it ensures patients choose the high-cost branded product over potentially lower-cost therapeutic alternatives.
This practice undermines the core cost-control strategies used by insurance plans. Plans that rely on benefit designs, such as tiered formularies, to steer patients toward less costly generics or preferred medications.
The American Society of Health-System Pharmacists (ASHP) has explicitly opposed drug marketing programs that encourage inappropriate prescribing habits or increase the cost of treatment for all patients. Manufacturers neutralize the financial incentive for both the patient and the prescriber to seek cheaper options by covering the patient’s cost sharing.
Payer Counter-Tactics: The War on Cost Sharing
- Copay Accumulator Programs
- These plans accept the manufacturer coupon value, but that value explicitly does not count toward the enrollee’s deductible or out-of-pocket maximum.
- Once the coupon funds are exhausted, the patient is instantly responsible for meeting the entirety of their high deductible, causing what’s known as “copay shock.”
- Copay Maximizer Programs
- These plans reclassify high-cost medications and set the patient’s annual cost sharing to match the maximum value of the coupon, applied evenly throughout the year.
- The assistance value does not count toward the deductible/maximum, allowing plans to capture the full coupon value while requiring the patient to pay the maximum possible co-pay before receiving the drug.
- Alternative Funding Programs (AFPs)
- For-profit programs marketed to self-funded employer insurance plans to minimize their specialty drug costs.
- AFPs operate by “carving out” specialty medications from the plan’s formulary, effectively making the patient appear uninsured or underinsured for that specific prescription drug. The patient is then immediately forced into a manufacturer sponsored or charitable PAP to obtain the drug.
Quantifiable Harms to Patients and Systems
Research from the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital and Harvard Medical School has clearly quantified the harmful effects of these programs:
- Price and Spending Increase:
- Copayment coupons raise negotiated net-of-rebate prices by 8% for certain categories of drugs (e.g., multiple sclerosis medications).
- The price increase, combined with higher use, results in increased U.S. spending. There is up to $1 billion more spending annually for that category alone, and up to 30% increased spending on couponed drugs without generic substitutes.
- Limited Financial Impact:
- A study analyzing prescriptions for oral anticancer medications demonstrated that the median amount of financial assistance provided by PAPs per prescription was $0, and only amounted to 15% of the median prescription cash price.
- Patient Financial Instability:
- Patients face a sudden, massive financial liability when insurance plans use counter-tactics that invalidate assistance from counting toward annual cost sharing limits.
- This unexpected financial instability significantly increases the risk of reduced medication adherence, potentially leading to poorer health outcomes and greater overall healthcare expenditures.
The Path Forward: Comprehensive Reform
- Stop Payer Mitigation: Mandate that all patient financial assistance for costly drugs must count toward deductibles and annual out-of-pocket maximums to ensure benefit integrity.
- Standardize PAPs: Pharmaceutical companies must standardize application criteria, eligibility, and processes, including clear, public income thresholds and documentation requirements.
- Address Root Causes: Sustainable change necessitates controlling high prescription drug list prices, not managing costs via charity. Focus legislative efforts on direct drug cost control, such as enhanced price negotiation and accelerating generic/biosimilar competition.
Beyond the Charity Model
Manufacturer-funded Patient Assistance Programs (PAPs) distort the market, driving up drug costs and undermining insurance cost-containment, a fact confirmed by Harvard Medical School research. True healthcare affordability requires structural policy reform, not fragmented charity, to enforce benefit integrity, protect patient cost-sharing, and, most importantly, compel lower initial prescription drug prices. Relying on PAPs concedes to unchecked pricing.
Healthcare organizations can take action now by implementing comprehensive patient financial services solutions that streamline assistance programs while advocating for broader policy reform.
